Pharmaceutical preparation comprising phenylalanine derivative
The disclosed pharmaceutical preparation comprises a compound represented by the chemical formula (A) or a pharmaceutically acceptable salt thereof, which is dispersed in a matrix consisting of a water-soluble high molecular weight substance; and Crospovidone: The pharmaceutical preparation is excellent in the solubility and the storage stability even if the amount of the compound or the salt included in each individual dosage unit is increased.
1. A pharmaceutical composition, comprising:
14 to 35% by mass, based on the total mass of the pharmaceutical composition, of a compound represented by the formula (A) or a pharmaceutically acceptable salt thereof dispersed in a matrix comprising 0.1 to 10 parts by mass of a water-soluble high molecular weight substance per one part by mass of the compound represented by the formula (A) or a pharmaceutically acceptable salt thereof,
1 to 15% by mass, based on the total mass of the pharmaceutical composition, of Crospovidone; and
10 to 600 parts by mass, per 100 parts by mass of the Crospovidone, of sodium Cros-carmellose,
wherein the pharmaceutical composition is in the form of a tablet and comprises not less than 100 mg of the compound represented by the formula (A) or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition of claim 1 , wherein the water-soluble high molecular weight substance is at least one member selected from the group consisting of methyl cellulose, hypromellose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose phthalate, hydroxypropyl-methyl cellulose acetate succinate, carboxymethyl-ethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl cellulose, cellulose acetate phthalate, polyethylene glycol, polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl-acetal diethylamino acetate, aminoalkyl methacrylate copolymer E, aminoalkyl methacryl copolymer RS, methacrylic acid copolymer L, methacrylic acid copolymer LD, methacrylic acid copolymer S, carboxy vinyl polymer, gum Arabic, sodium alginate, alginic acid propylene glycol ester, agar, gelatin, tragacanth gum, and xanthane gum.
3. The pharmaceutical composition of claim 1 , wherein the water-soluble high molecular weight substance is at least one member selected from the group consisting of methyl cellulose, hypromellose, hydroxypropyl cellulose, polyethylene glycol, polyvinyl alcohol and polyvinyl pyrrolidone.
4. The pharmaceutical composition of claim 1 , which comprises a granulated product formed from a dispersion obtained by dispersing the compound represented by the formula (A) or a pharmaceutically acceptable salt thereof in the matrix, and Crospovidone.
5. The pharmaceutical composition of claim 1 , further comprising:
an excipient.
6. The pharmaceutical composition of claim 5 , wherein the excipient is at least one member selected from the group consisting of mannitol, pregelatinized starch and crystalline cellulose.
7. The pharmaceutical composition of claim 1 , wherein the surface of the tablet is coated with a coating agent.
8. The pharmaceutical composition of claim 7 , wherein the coating agent is at least one member selected from the group consisting of aminoalkyl methacrylate copolymer E, hypromellose, methyl cellulose, methyl-hydroxyethyl cellulose, Opadry, calcium carmellose, sodium carmellose, polyvinyl pyrrolidone, polyvinyl alcohol, dextrin, pullulan, gelatin, agar and gum Arabic.
9. The pharmaceutical composition of claim 1 , wherein the water-soluble high molecular weight substance is methylcellulose.
10. The pharmaceutical composition of claim 1 , which comprises 14 to 30.1% by mass, based on the total mass of the pharmaceutical composition, of the compound represented by the formula (A) or a pharmaceutically acceptable salt thereof, and 50 to 600 parts by mass, per 100 parts by mass of the Crospovidone, of sodium Cros-carmellose.
11. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises not less than 200 mg of the compound represented by the formula (A) or a pharmaceutically acceptable salt thereof.
12. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises 120 mg to 240 mg of the compound represented by the formula (A) or a pharmaceutically acceptable salt thereof.
13. A method of treating an inflammatory disease, comprising:
administering an effective amount of the pharmaceutical composition of claim 1 to a subject in need thereof.
14. A method of treating Crohn's disease, ulcerative colitis, systemic lupus erythematosus, disseminated or multiple sclerosis, Sjogren's syndrome, asthma, psoriasis, allergy, diabetes mellitus, cardiovascular diseases, arterial sclerosis, restenosis, tumor hyperplasia, tumor metastasis or graft rejection, comprising:
administering an effective amount of the pharmaceutical composition of claim 1 to a subject in need thereof.
15. The pharmaceutical composition of claim 1 , further comprising:
partially pregelatinized starch;
crystalline cellulose; and
mannitol,
wherein the water-soluble high molecular weight substance is methyl cellulose.
16. The pharmaceutical composition of claim 10 , further comprising:
partially pregelatinized starch;
crystalline cellulose; and
mannitol,
wherein the water-soluble high molecular weight substance is methyl cellulose.
17. The pharmaceutical composition of claim 1 , further comprising:
pregelatinized starch;
crystalline cellulose; and
mannitol,
wherein the tablet is coated with a coating agent comprising hypromellose,
the water-soluble high molecular weight substance is methyl cellulose and is included in the matrix in an amount of 1 to 3 parts by mass per one part by mass of the compound represented by the formula (A) or a pharmaceutically acceptable salt thereof, and
an amount of the coating agent is 1 to 7% by mass, based on the total mass of the pharmaceutical composition.